Brokerages Expect Theravance Biopharma, Inc. (NASDAQ:TBPH) Will Post Quarterly Sales of $16.39 Million

Equities research analysts predict that Theravance Biopharma, Inc. (NASDAQ:TBPHGet Rating) will announce $16.39 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Theravance Biopharma’s earnings, with the lowest sales estimate coming in at $14.88 million and the highest estimate coming in at $17.90 million. Theravance Biopharma posted sales of $12.91 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 27%. The firm is expected to issue its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Theravance Biopharma will report full year sales of $98.45 million for the current financial year, with estimates ranging from $92.11 million to $104.79 million. For the next year, analysts anticipate that the firm will post sales of $87.33 million, with estimates ranging from $68.56 million to $123.15 million. Zacks’ sales calculations are a mean average based on a survey of research firms that follow Theravance Biopharma.

Theravance Biopharma (NASDAQ:TBPHGet Rating) last issued its quarterly earnings results on Wednesday, February 23rd. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.13). The firm had revenue of $14.95 million for the quarter, compared to analyst estimates of $15.59 million. During the same quarter in the previous year, the company earned ($0.92) earnings per share.

TBPH has been the topic of several research reports. HC Wainwright increased their price target on shares of Theravance Biopharma from $8.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, February 24th. Morgan Stanley upped their target price on shares of Theravance Biopharma from $10.00 to $11.00 and gave the stock an “underweight” rating in a research note on Wednesday, March 2nd. Finally, StockNews.com initiated coverage on shares of Theravance Biopharma in a research note on Thursday, March 31st. They set a “hold” rating on the stock. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $11.06.

Institutional investors and hedge funds have recently made changes to their positions in the company. Acadian Asset Management LLC grew its position in shares of Theravance Biopharma by 51.6% during the first quarter. Acadian Asset Management LLC now owns 8,277 shares of the biopharmaceutical company’s stock worth $77,000 after acquiring an additional 2,818 shares during the last quarter. BNP Paribas Arbitrage SA grew its position in shares of Theravance Biopharma by 420.5% during the third quarter. BNP Paribas Arbitrage SA now owns 10,790 shares of the biopharmaceutical company’s stock worth $80,000 after acquiring an additional 8,717 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Theravance Biopharma by 49.5% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,548 shares of the biopharmaceutical company’s stock worth $82,000 after acquiring an additional 2,830 shares during the last quarter. Rafferty Asset Management LLC purchased a new position in shares of Theravance Biopharma during the third quarter worth approximately $94,000. Finally, Principal Financial Group Inc. acquired a new stake in shares of Theravance Biopharma during the first quarter worth $101,000. Institutional investors and hedge funds own 78.14% of the company’s stock.

Shares of TBPH traded up $0.11 during mid-day trading on Wednesday, hitting $9.12. 360,010 shares of the company’s stock were exchanged, compared to its average volume of 570,306. The company has a market cap of $692.21 million, a price-to-earnings ratio of -4.45 and a beta of 0.78. Theravance Biopharma has a fifty-two week low of $6.10 and a fifty-two week high of $19.03. The stock’s 50-day moving average is $9.68 and its 200-day moving average is $9.54.

Theravance Biopharma Company Profile (Get Rating)

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.

Read More

Get a free copy of the Zacks research report on Theravance Biopharma (TBPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.